205 related articles for article (PubMed ID: 31328328)
1. Identifying pregnancies in insurance claims data: Methods and application to retinoid teratogenic surveillance.
MacDonald SC; Cohen JM; Panchaud A; McElrath TF; Huybrechts KF; Hernández-Díaz S
Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1211-1221. PubMed ID: 31328328
[TBL] [Abstract][Full Text] [Related]
2. Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations.
Charlton RA; Weil JG; Cunnington MC; Ray S; de Vries CS
Drug Saf; 2011 Feb; 34(2):157-71. PubMed ID: 21247222
[TBL] [Abstract][Full Text] [Related]
3. Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy.
Schaefer C; Meister R; Weber-Schoendorfer C
Arch Gynecol Obstet; 2010 Feb; 281(2):221-7. PubMed ID: 19444462
[TBL] [Abstract][Full Text] [Related]
4. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy.
Loureiro KD; Kao KK; Jones KL; Alvarado S; Chavez C; Dick L; Felix R; Johnson D; Chambers CD
Am J Med Genet A; 2005 Jul; 136(2):117-21. PubMed ID: 15940677
[TBL] [Abstract][Full Text] [Related]
5. Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies.
Sarayani A; Albogami Y; Thai TN; Smolinski NE; Patel P; Wang Y; Nduaguba S; Rasmussen SA; Winterstein AG
Am J Obstet Gynecol; 2022 Aug; 227(2):263.e1-263.e38. PubMed ID: 35032444
[TBL] [Abstract][Full Text] [Related]
6. Isotretinoin exposure during pregnancy: assessment of spontaneous reports in France.
Autret-Leca E; Kreft-Jais C; Elefant E; Cissoko H; Darrouzain F; Grimaldi-Bensouda L; Attia S; Jonville-Béra AP
Drug Saf; 2010 Aug; 33(8):659-65. PubMed ID: 20635824
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology of isotretinoin exposure during pregnancy.
Dai WS; LaBraico JM; Stern RS
J Am Acad Dermatol; 1992 Apr; 26(4):599-606. PubMed ID: 1597546
[TBL] [Abstract][Full Text] [Related]
8. Safety of pregnancy after discontinuation of isotretinoin.
Dai WS; Hsu MA; Itri LM
Arch Dermatol; 1989 Mar; 125(3):362-5. PubMed ID: 2923442
[TBL] [Abstract][Full Text] [Related]
9. [Isotretinoin (Roaccutane) in women of childbearing age: failure of following prescription guidelines].
Autret E; Radal M; Jonville-Béra AP; Goehrs JM
Ann Dermatol Venereol; 1997; 124(8):518-22. PubMed ID: 9740842
[TBL] [Abstract][Full Text] [Related]
10. Isotretinoin: Still the cause of anxiety for teratogenicity.
Altıntaş Aykan D; Ergün Y
Dermatol Ther; 2020 Jan; 33(1):e13192. PubMed ID: 31837244
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data.
Hoeltzenbein M; Beck E; Rajwanshi R; Gøtestam Skorpen C; Berber E; Schaefer C; Østensen M
Semin Arthritis Rheum; 2016 Oct; 46(2):238-245. PubMed ID: 27346577
[TBL] [Abstract][Full Text] [Related]
12. Use of existing electronic health care databases to evaluate medication safety in pregnancy: Triptan exposure in pregnancy as a case study.
Yusuf A; Chia V; Xue F; Mikol DD; Bollinger L; Cangialose C
Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1309-1315. PubMed ID: 30240072
[TBL] [Abstract][Full Text] [Related]
13. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective.
Bérard A; Azoulay L; Koren G; Blais L; Perreault S; Oraichi D
Br J Clin Pharmacol; 2007 Feb; 63(2):196-205. PubMed ID: 17214828
[TBL] [Abstract][Full Text] [Related]
14. Retinoic acid embryopathy.
Lammer EJ; Chen DT; Hoar RM; Agnish ND; Benke PJ; Braun JT; Curry CJ; Fernhoff PM; Grix AW; Lott IT
N Engl J Med; 1985 Oct; 313(14):837-41. PubMed ID: 3162101
[TBL] [Abstract][Full Text] [Related]
15. Development of an algorithm to identify pregnancy episodes and related outcomes in health care claims databases: An application to antiepileptic drug use in 4.9 million pregnant women in France.
Blotière PO; Weill A; Dalichampt M; Billionnet C; Mezzarobba M; Raguideau F; Dray-Spira R; Zureik M; Coste J; Alla F
Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):763-770. PubMed ID: 29763992
[TBL] [Abstract][Full Text] [Related]
16. Face-to-face: isotretinoin use and pregnancy outcome.
Tırmıkçıoğlu Z; Tatlıparmak A
Int J Dermatol; 2024 Feb; 63(2):232-238. PubMed ID: 38095245
[TBL] [Abstract][Full Text] [Related]
17. Use of isotretinoin among girls and women of childbearing age and occurrence of isotretinoin-exposed pregnancies in Germany: A population-based study.
Reinold J; Kollhorst B; Wentzell N; Platzbecker K; Haug U
PLoS Med; 2024 Jan; 21(1):e1004339. PubMed ID: 38271295
[TBL] [Abstract][Full Text] [Related]
18. A new perspective on isotretinoin in pregnancy: Pregnancy outcomes, evaluation of complex phenotypes, and importance of teratological counselling.
Alay MT; Kalayci A; Seven M
Eur J Obstet Gynecol Reprod Biol; 2023 Dec; 291():148-155. PubMed ID: 37890418
[TBL] [Abstract][Full Text] [Related]
19. [Isotretinoin: compliance with recommendations in childbearing women].
Bensouda-Grimaldi L; Jonville-Béra AP; Mouret E; Elefant E; Dhellot H; Delmas C; Gouin T; Coste P; Autret-Leca E;
Ann Dermatol Venereol; 2005 May; 132(5):415-23. PubMed ID: 15988352
[TBL] [Abstract][Full Text] [Related]
20. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study.
Winterfeld U; Allignol A; Panchaud A; Rothuizen LE; Merlob P; Cuppers-Maarschalkerweerd B; Vial T; Stephens S; Clementi M; De Santis M; Pistelli A; Berlin M; Eleftheriou G; Maňáková E; Buclin T
BJOG; 2013 Mar; 120(4):463-71. PubMed ID: 23194157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
